Skip to main content

Arteriovenous Malformation

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
1
68Ga-NEBPhase 11 trial
Active Trials
NCT02496013Unknown70Est. Dec 2017
Genomics
GenomicsUK - Oxford
1 program
Genetics of Arteriovenous MalformationsN/A1 trial
Active Trials
NCT02445430Unknown59Est. Jun 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
UNION therapeutics68Ga-NEB
GenomicsGenetics of Arteriovenous Malformations

Clinical Trials (2)

Total enrollment: 129 patients across 2 trials

Clinical Translation of a Novel Albumin-Binding PET Radiotracer 68Ga-NEB

Start: Jan 2014Est. completion: Dec 201770 patients
Phase 1Unknown
NCT02445430GenomicsGenetics of Arteriovenous Malformations

Genetics of Arteriovenous Malformations

Start: May 2015Est. completion: Jun 202359 patients
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.